A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Participants With Non-Small Cell Lung Cancer
NCT ID: NCT06068842
Last Updated: 2025-01-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
579 participants
OBSERVATIONAL
2023-11-03
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Archived tissue biopsies will be tested for MET OE and data from approximately 500 participants will be collected. No participants will be enrolled in this study.
Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the study will be approximately 15 months.
There is no additional burden for participants in this trial.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluating Mutations in MET and TP53 Among Patients Diagnosed With Squamous Cell Carcinoma
NCT03938012
Study of Tumor Samples From Patients With Lung Cancer
NCT00900328
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China
NCT03059641
Multinational Observational Study to Describe Diagnostic Stage Shift in Patients With Lung Cancer Using Medical Records
NCT06842056
CTC in Lung Caner Patients With Bone Metastases
NCT04568291
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants Undergoing Chart Review
Participants treated for non small cell lung cancer undergoing chart review and retrospective mesenchymal epithelial transition (MET) overexpression (OE) testing of tissue biopsies.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed advanced and/or metastatic non-squamous (NSQ) non-small cell lung cancer (NSCLC).
* Has formalin-fixed paraffin-embedded (FFPE) tissue collected since 2019.
Exclusion Criteria
* Insufficient specimen tissue for testing.
* Insufficient specimen quality (e.g., not 4-5 µm in thickness) which precludes testing.
* Adenosquamous and sarcomatous histologies of NSCLC.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ABBVIE INC.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Italiano de Buenos Aires /ID# 256999
Ciudad Autonoma Buenos Aires, Buenos Aires F.D., Argentina
Instituto Alexander Fleming /ID# 256295
Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., Argentina
Irmandade da Santa Casa de Misericordia de Porto Alegre /ID# 256487
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Alemao Oswaldo Cruz /ID# 256486
São Paulo, , Brazil
Nova Scotia Health Authority /ID# 256950
Halifax, Nova Scotia, Canada
Institut universitaire de cardiologie et de pneumologie de Québec - Université L /ID# 257872
Québec, Quebec, Canada
Royal University Hospital /ID# 261272
Saskatoon, Saskatchewan, Canada
West China Hospital, Sichuan University /ID# 256906
Chengdu, Sichuan, China
Rambam Health Care Campus /ID# 256546
Haifa, H_efa, Israel
Kindai University Hospital /ID# 257890
Osakasayama-shi, Osaka, Japan
National Cancer Center Hospital /ID# 257889
Chuo-ku, Tokyo, Japan
The Catholic University of Korea, Yeouido ST. Mary's Hospital /ID# 261511
Seoul, Seoul Teugbyeolsi, South Korea
UOMi Cancer Center - Clinica Tres Torres /ID# 261212
Barcelona, , Spain
Universitätsspital Basel /ID# 256677
Basel Town, Canton of Basel-City, Switzerland
University Hospital Zurich /ID# 256678
Zurich, Canton of Zurich, Switzerland
National Taiwan University Hospital /ID# 261542
Taipei City, Taipei, Taiwan
Burjeel Medical City /ID# 259407
Abu Dhabi, , United Arab Emirates
Queen's University Belfast /ID# 258458
Belfast, Northern Ireland, United Kingdom
University Hospitals Birmingham NHS Foundation Trust /ID# 260991
Birmingham, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H24-281
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.